Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in Colorado: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 139 | 46% |
| 2020 | 1 | 148 | 48% |
| 2021 | 1 | 149 | 50% |
| 2022 | 1 | 152 | 53% |
| 2023 | 0 | 144 | 55% |
| 2024 | 0 | 122 | 57% |
| 2025 from claims | – | 135 109–159 | 57% |
| 2026 forecast | – | 141 110–177 | 56% |
| 2027 forecast | – | 143 106–189 | 56% |
| 2028 forecast | – | 145 103–200 | 57% |
| 2029 forecast | – | 147 100–211 | 57% |
| 2030 forecast | – | 149 98–221 | 57% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 8 | 940−1.6%/yr | −1.6%/yr | 0.3 | 0% | 1,020 in 2030+1.4%/yr |
| Arizona | 3 | 264+12%/yr | +12%/yr | 0.4 | 0% | 460 in 2030+9.6%/yr |
| Utah | 1 | 173+29%/yr | +29%/yr | 0.8 | 79% | 280 in 2030+8.3%/yr |
| Washington | 0 | 149−4.5%/yr | −4.5%/yr | 0.2 | 0% | 40 in 2030−20%/yr |
| Oregon | 0 | 120+0.7%/yr | +0.7%/yr | 0.3 | 0% | 140 in 2030+2.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 51 | 3,013−3.3%/yr | −3.3%/yr | 6.61.0× | 36% | 3,380 in 2030+1.9%/yr |
| Tumor & fibroid embolization | 4 | 415+7.6%/yr | +7.6%/yr | 0.91.6× | 70% | 820 in 2030+12%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in Colorado · Every state · Compare with California
Trisalus Life Sciences leads with 51% of company spending on these surgeons in 2025, −9 pts on 2024.
In 2025, 17 companies reported engagement with Colorado’s surgeons worth $192K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.